Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,039.96 +8.81 (+0.85%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 6 Next > Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024 Today 16:05 EDT From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old September 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) September 13, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Biotech Breakout: Stocks for Your Watchlist September 12, 2024 The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. Via MarketBeat Topics ETFs EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile September 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) September 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial September 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer September 09, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO September 09, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma August 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases August 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Provides Update on Biologics License Application for Linvoseltamab August 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast August 07, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Reports Second Quarter 2024 Financial and Operating Results August 01, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation July 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire CPI Data Sparks Rally in Biotech Stocks July 15, 2024 Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. Via MarketBeat Topics ETFs Economy Exposures Interest Rates Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD July 03, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma June 28, 2024 Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell... From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 June 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine June 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma June 16, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) June 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD May 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation May 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO May 23, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine May 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm May 19, 2024 From Bragar Eagel & Squire Via GlobeNewswire More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 May 17, 2024 Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) May 16, 2024 From Kirby McInerney LLP Via Business Wire Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) May 13, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.